M&A Deal Summary |
|
|---|---|
| Date | 2021-06-29 |
| Target | BayMedica |
| Sector | Life Science |
| Buyer(s) | InMed Pharmaceuticals |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1981 |
| Sector | Life Science |
| Employees | 13 |
| Revenue | 5M USD (2024) |
InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), and is developing IntegraSyn™ to produce pharmaceutical-grade cannabinoids. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. InMed Pharmaceuticals was formed in 1981 and is based in Vancouver, British Columbia.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: Nevada M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2021 M&A | 1 of 1 |